Tes Pharma Presents Results on TES-ONC-07 at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Solomeo-Corciano (PG), Italy, April 18, 2025 – Tes Pharma, a biotech company focused on delivering first-in class therapeutics for high unmet medical needs in oncological, metabolic and renal diseases, today announced that a poster presentation will be delivered on the Company’s product candidate TES-ONC-07 at the 2025 American Association for Cancer Research Annual Meeting taking place April 25-30, 2025, in Chicago, IL.
“We are pleased to share the latest data from our lead compound TES-ONC-07, currently investigated as an innovative approach for cancer immunotherapy” said Andrea Pellacani, Chief Medical Officer at Tes Pharma. “These data strongly suggest that the inhibition of the orphan nuclear receptor NR2F6 enhances the capability of the immune cells to infiltrate tumors and effectively attack cancer cells, especially in a tumor model that is resistant to currently approved immune checkpoint inhibitors”.
Title: First-in-class NR2F6 antagonist TES-ONC-07 enhances anti-cancer host immunity reducing tumor growth in a “cold” cancer model
Lead Author: Greco Francesco A., PhD, NR2F6 Project Leader, Tes Pharma
Session Title: Therapeutic Approaches to Attack the Tumor Microenvironment
Date/Time: Monday, April 28, 2025, from 2:00 p.m. – 5:00 p.m. CST
More information about this abstract will be made available after the respective embargoes, as set by the AACR organizers, are lifted for each presentation.
About TES-ONC-07
TES-ONC-07 is a potent and selective first-in-class modulator of the orphan nuclear receptor NR2F6. This protein is upregulated in tumor infiltrating lymphocytes (TILs) and it has emerged as a key factor that reduces the activation of TILs against cancer. Since NR2F6 expression is limited in peripheral immune cells, it represents a tumor-inducible valuable target for novel immunotherapy approaches. Indeed, NR2F6 expression inversely correlates with reduced immune infiltration in several human cancers.
Treatment with TES-ONC-07 increases activation levels of T cells ex vivo and immune infiltration in “cold” tumors, resulting in reduced cancer growth in immunotherapy-resistant cancer models.
About Tes Pharma
Tes Pharma is a biotech company focused on delivering first-in-class therapeutics for high unmet medical needs in metabolic, renal diseases and oncology. Tes Pharma’s clinically validated drug discovery engine generates rationally designed drug candidates for novel targets. Tes Pharma has a long-standing partnership with Intercept for the discovery and development of bile acid derivatives for the treatment of liver disease. INT-787 is undergoing Phase 2 clinical studies for the treatment of severe alcohol-associated hepatitis (sAH). Separate from the collaboration with Intercept, Tes Pharma is also developing TES-AKI-01 and TES-ONC-07, two first-in-class small molecules for the treatment of acute kidney injury and for cancer immunotherapy, respectively, that are entering IND-enabling studies. Also, Tes Pharma has an undisclosed pipeline of additional projects in the early phase of drug discovery.
For more information, please visit www.tespharma.com or connect with the Company on LinkedIn
For further information, please contact:
Sara Malincarne
smalincarne@tespharma.com